|
SPECIAL
EXPERTISE :
Preclinical
program management, preparation of US FDA regulatory IND submissions
to allow entry into the clinic and set-up and management of
Phase I and II clinical trials.
Over
10 years of clinical trials experience. Therapeutic areas
of experience include HIV, HBV, bacterial infection and autoimmune
and renal disease, encompassing the development of both small
molecule and biologic products.
| PROGRAM
MANAGEMENT EXPERIENCE |
- Provided
project direction, leadership for the preclinical
toxicology assessment, manufacture and clinical development
of biopharmaceutical products.
- Identified
product development strategies, risk and provided
options to limit risk.
- Identified
critical tasks and resources.
- Ensured
that the project timeline was met and the quality
of work maintained in a cost effective manner.
- Prepared
and negotiated contracts with contractors resulting
in substantial cost savings to the Sponsor.
- Prepared
budget proposals, organized resources and tracked
resource usage, prepared and maintained Gantt charts.
- Organized
and led project team meetings.
- Managed
and developed an excellent working relationship with
contractors (CROs, CMOs, Contract Laboratories, Data
management contractors) with considerable positive
feedback
|
| REGULATORY
AFFAIRS EXPERIENCE |
- Assessed
biopharmaceutical products and platform technologies
including:
- Assessment
of preclinical data, CMC data, clinical trial
design and study protocols.
- Literature
review of scientific and clinical information.
- Review
of grant applications.
- Assisted
in the identification and preparation of an appropriate
regulatory strategy, product development plan and
clinical development plan (CDP).
- Contributed
to design of preclinical pharmacodynamic and toxicology
studies.
- Authored
FDA pre-IND meeting and IND submissions, which included:
- Preclinical
pharmacology and toxicology section.
- Clinical
section; CDP, study protocols, Investigator's
Brochure.
- CMC
information; GMP manufacture.
- Prepared
FDA meeting request letters.
- Correspond
with FDA reviewers.
- Prepared
FDA IND amendments.
- Searched
and interpreted FDA guidelines.
- Reviewed
Biologic Master Files.
- Provided
QA function:
- Review
of SOPs.
- GLP
training.
- Review
of preclinical study design, protocols and batch
records.
- Review
of research study conduct.
|
| CLINICAL
EXPERIENCE |
- Project
Management:
- Provided
clinical project management for single and multi-site
Phase I and II studies in the US and Australia.
- Led
clinical trial team of regulatory and clinical
experts.
- Directly
supervised CRAs.
- Study
Set-up:
- Designed
and/or authored (phase I/II) protocols and Case
Report Forms (CRFs), Regulatory and Master File
essential documents, Clinical Monitoring Plans,
Study Manuals and Monitoring Guidelines.
- Organized
and presented at investigator meetings.
- Prepared
Institutional Review Board (IRB) applications
including informed consent (ICF) documents.
- Initiated
sites; visited sites to prepare staff for conducting
studies and enrolling subjects.
- Trained
CRAs and study coordinators.
- Planned
the supply, randomization procedure and dispensing
of investigational agent (study product).
- Site
Selection:
- Prepared
RFPs for study sites and reviewed proposals.
- Identified
and recruited potential investigators and evaluated
sites.
- Constructed
clinical trial budgets and reviewed site budget
proposals.
- Negotiated
site budgets to minimize Sponsor costs.
- Ongoing
Study Management:
- Identified
recruitment strategies and improved subject recruitment.
- Communicated
with investigators, developed and maintained strong
working relationship with investigator and study
coordinators.
- Managed
study sites, ensured ongoing prospective assessment
of study issues, and took corrective action where
required.
- Monitored
sites and verified the integrity of clinical data.
- Ensured
that sites were conducting studies in accordance
with the protocol, GCP, ICH and FDA guidelines.
- Tracked
study progress and improved site performance by
ongoing review of study data (review of Data Management
tracking tools) and follow-up with CRAs, investigators
and coordinators to take corrective action.
- Generated
study newsletters, progress and meeting reports.
|
| CELL
BIOLOGY, CELLULAR IMMUNOLOGY EXPERIENCE |
-
Contributed to the overall team development of a peptide
vaccine, for the treatment of patients chronically
infected with Hepatitis B virus.
- Prepared
detailed technical reports and scientific papers.
- Analyzed
and interpreted results.
- Developed
problem-solving skills.
- Devised
hypotheses and planned research projects.
- Developed
Bioassays
|
|
EDUCATION
| Ph.D. |
|
University
of Melbourne, Walter and Eliza Hall Institute for Medical
Research, Melbourne, Australia (1987-1990) |
| M.App.Sc. |
|
Cancer
Institute, Peter MacCallum Hospital, Melbourne, Australia
(1983-1985) |
| B.App.Sc. |
|
Swinburne
Institute, Biochemistry and Chemistry (1979-1982) |
HONORS
AND AWARDS:
| 2001 |
|
Excellence
award, CSG diabetic nephropathy trial |
| 1993 |
|
Cytel
Financial Award, for contribution to the HBV project |
| 1987-1990 |
|
University
of Melbourne Postgraduate Scholarship |
EXPERIENCE:
CURRENT
POSITION:
2002 to present: |
|
Consultant,
Biologics Consulting Group Inc.
San Mateo, CA USA (Sept. 2002 - present)
|
| |
|
|
| Sept
1999 to Sept 2002 |
|
Clinical
Research Associate, Laboratories Fournier SA, Bondi
Junction, NSW Australia. |
| |
|
|
| May
1997 to Dec 2000 |
|
Pacific
Project Coordinator, Collaborative Study Group,
Monash Medical Centre, Melbourne, Australia.
|
| |
|
|
| Aug.
1996 to Dec. 1996 |
|
Project
Manager, Narhex Operations Pty. Ltd., Sydney, Australia.
|
| |
|
|
| Dec.
1994 to July 1996 |
|
Business
Manager , VYMP Pty. Ltd., Melbourne, Australia.
|
| |
|
|
| Mar.
1994 to Nov. 1994 |
|
Clinical
Trial Coordinator, Western Hospital, Melbourne,
Australia.
|
| |
|
|
| Jan.
1992 to Jun. 1993 |
|
Postdoctoral
Research Scientist, Cytel Corporation, San Diego,
CA.
|
| |
|
|
| Jan
1991 to Dec. 1991 |
|
Postdoctoral
Research Scientist, Whittier Institute, Scripps Hospital,
San Diego, CA. |
|
| BIBLIOGRAPHY:
|
| 1. |
|
Vitiello
A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, Yuan
L, Chisari, FV, Furze J, Bartholomeusz R, Chesnut, RW.
Development of a lipopeptide-based therapeutic vaccine
to treat chronic HBV infection. I. Induction of a primary
cytotoxic T lymphocyte response in humans. J Clin Invest.
1995 Jan; 95(1):341-9. |
| |
|
|
| 2. |
|
Kielczynski
W, Bartholomeusz RK, Harrison LC. Characterization of
ganglioside associated with the thyrotrophin receptor.
Glycobiology. 1994 Dec;4(6):791 6. |
| |
|
|
| 3. |
|
Allison
J, Malcolm L, Culvenor J, Bartholomeusz RK, Holmberg K,
Miller JF. Overexpression of beta 2 microglobulin in transgenic
mouse islet beta cells results in defective insulin secretion.
Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2070 4. |
| |
|
|
| 4. |
|
Bartholomeusz
RK, Campbell IL, Harrison LC. A2135 reactive ganglioside
expression determines the differentiation stage and capacity
of rat insulinoma (RIN) sublines. Cell Differ Dev. 1990
Oct;32(1):39 46. |
| |
|
|
| 5. |
|
Bartholomeusz
RK, Campbell IL, Harrison LC. A2135 reactive ganglioside
expression is an index of differentiation in rat insulinoma
(RIN) cells. Endocrinology. 1990 Apr;126(4):1927 33. |
| |
|
|
| 6. |
|
Bartholomeusz
RK, Campbell IL, Harrison LC. Pancreatic islet A2B5 and
3G5 reactive gangliosides are markers of differentiation
in rat insulinoma cells. Endocrinology. 1989 Jun;124(6):2680
5. |
| |
|
|
| 7. |
|
Bartholomeusz
RK, Bertoncello I, Chamley WA. A correlation between ovarian
follicular maturity and anchorage independent growth of
bovine granulosa cells. Int J Cell Cloning. 1988 Mar;
6(2):106 15. |
| |
|
|
| 8. |
|
Bartholomeusz
RK, Bertoncello 1. Anchorage independence as an index
of proliferative potential and maturational age: a comparison
of the growth of normal, primary explanted bovine granulosa
cells in semisolid agar and in liquid culture. Int J Cell
Cloning. 1987 Mar;5(2):142 8. |
| |
|
|
| 9. |
|
Type
I diabetes: Immunopathology and Immunotherapy. Harrison
LC, Campbell IL, Colman PG, Chosich N, Kay TW, Tait BD,
Bartholomeusz RK, DeAizpurua HJ, Joseph JL, Chu S and
Kielczynski WE. In Advances in Endocrinology and Metabolism.
Eds. EL Mazzaferri, RS Bar and RA Kreisberg. Voll, 1990,
p36 94. (Mosby Year Book Inc) |
| |
|
Page
Updated:
October 3, 2007
|
|